LifeScience Antibody Drug Conjugates

Merck Invests €70 Million to Triple ADC Manufacturing Capacity at St. Louis Facility, Bolstering Bioconjugation Excellence

Merck, a leading science and technology company, announced a € 70 million expansion of its ADC manufacturing capabilities and capacity at its Bioconju...

 October 30, 2024 | News

Merck Introduces First Single-Use Reactor Tailored for Antibody-Drug Conjugate (ADC) Manufacturing

First scalable single-use mixer specifically designed for ADC manufacturing Increases efficiency by 70% compared to stainless steel or glass manufacturi...

 October 04, 2024 | News

Astellas Pharma Gains NMPA Approval for PADCEV™ in China to Treat Advanced Urothelial Cancer

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas")  announced that the Center for Drug Evaluation (CDE) of C...

 August 20, 2024 | News

Mabwell's Nectin-4 Targeting ADC Receives Breakthrough Therapy Designation in China for Urothelial Carcinoma

Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced its novel Nectin-4 targeting ADC (R&D code: 9MW2821)...

 August 13, 2024 | News

Sanyou Bio and Huadong Medicine Advance SYHD001 ADC Drug to Phase I Clinical Trials

Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "Sanyou Bio") has recently announced a significant milestone in collaboration wi...

 July 17, 2024 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close